Subject to change.
Subject to change.
Mark is the Head of Computational Pathology Strategic Partnerships where he leads teams to deliver next-generation computational pathology approaches. Prior to that, he was part of AstraZeneca groups delivering Biomarkers and Companion Diagnostics. Before AstraZeneca, Mark worked at the FDA as well as various computational pathology companies. Mark received his Ph.D. in Cancer Biology from Vanderbilt University and did his post-doctoral fellowship under Dr. David Rimm at Yale University.